Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 69

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 69
---
 entered into a warrant amendment agreement with an institutional investor to amend warrants to purchase up to 172,836 Common Shares,
adjusting the definition of a “Fundamental Transaction” and the exercise price to CHF 0.80 (the “September Warrant Amendment”).
In exchange for the September Warrant Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.02, and
following the Company increasing its authorized Common Shares, issued to the investor, pre-funded warrants to purchase up to 191,431 shares
of Common Shares.

On October 9, 2024, we
entered into a securities purchase agreement with certain accredited investors. Under this agreement, we issued and sold 806,452 Common
Shares and warrants to purchase an additional 806,452 Common Shares, at a combined purchase price of $3.97, for aggregate gross proceeds
of $3.2 million. The warrants have a term of five years and an exercise price of $4.25 per share. Investors were granted the
right to participate in up to 50% of future offerings for one year following the closing. We also agreed not to enter into an equity line
of credit or similar agreement without the consent of the majority of the preferred shareholders. The transaction closed on October 10,
2024.

Also on October 9, 2024,
we entered into a securities purchase agreement with an accredited investor to satisfy $4.0 million of our debt by issuing 806,452
newly designated convertible Preferred Shares at a purchase price of $4.96 per share (the “Preferred Shares”). The Preferred
Shares have a conversion price of $4.96 per share. The investor was granted the right to purchase up to an additional $10.0 million
worth of convertible Preferred Shares starting six months after the closing and continuing as long as they own Preferred Shares.
The investor also has the right to participate in up to 50% of future offerings for one year following the closing. We agreed not to enter
into an equity line of credit or similar agreement without the consent of the majority of the preferred shareholders. This transaction
also closed on October 10, 2024.

<div align='center'>II-2</div>

On October 9, 2024, we
and certain existing warrant holders entered into warrant amendment agreements (collectively, the “October Warrant Amendment”),
to amend those warrants issued by Company to such holders, collectively, to purchase